Bio-Techne Corp (TECH) Stock Analysis

Q: What is the TECH stock price target?

Take-profit $62.88 (+15.0% upside). Prior stop was $50.84.

Q: What are the risks of investing in TECH?

Earnings in 6 days (event risk); Weak overall score: 4.7/10; Weak growth; Momentum score 1.5/10 — below 4.5 minimum; EARNINGS_PROXIMITY:6d<=7d.

Q: Is TECH overvalued or undervalued?

Bio-Techne Corp trades at a P/E of 98.0 (forward 24.0). TrendMatrix value score: 5.1/10. Overall verdict: Sell.

Q: What do analysts say about TECH?

23 analysts cover TECH with a consensus score of 4.0/5. Average price target: $72.

Range Bound setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $54.71 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 6 days (event risk); Weak overall score: 4.7/10.

Bio-Techne develops and manufactures life science reagents, instruments, and services across Protein Sciences (~72% of FY2025 net sales) and Diagnostics & Spatial Biology (~28%) segments. Customers include pharmaceutical/biotech companies and academic researchers globally. No... Read more

$54.71+15.0% A.UpsideScore 4.7/10#118 of 158 Biotechnology

Stop $50.84Target $62.88(analyst − 13%)A.R:R 1.5:1

Analyst target$72.27+32.1%11 analysts

$62.88our TP

$54.71price

$72.27mean

$80

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

Strong earnings beat streak (3/4)

Risks

Earnings in 6 days (event risk)

Weak overall score: 4.7/10

Weak growth

Key Metrics

P/E (TTM)98.0

P/E (Fwd)24.0

Mkt Cap$8.1B

EV/EBITDA25.1

Profit Mgn6.7%

ROE4.0%

Rev Growth-0.4%

Beta1.49

Dividend0.62%

Rating analysts23

Quality Signals

Piotroski F8/9

Options Flow

P/C6.35bearish

IV70%elevated

Max Pain$40-26.9% vs spot

Material Events(8-K, last 90d)

2026-02-11Item 5.02MEDIUM
Dr. Matt McManus (President, Diagnostics & Spatial Biology) transitioning out effective March 1, 2026. Steve Crouse (SVP, Analytical Solutions Division) appointed as successor DSS President. No reason cited for McManus departure.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.115%0.76

Quality6.215%0.93

Growth3.115%0.46

Momentum1.510%0.15

Sentiment7.010%0.70

Insider Activity5.010%0.50

Peer Rank3.410%0.34

Technical Setup6.15%0.30

Risk Profile3.45%0.17

Catalyst7.05%0.35

Overall (Σ contributions)4.67

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

2.2

Rsi

4.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.0%/30d) — pullback in uptrend, not confirmed weakness

Revenue shrinking — -0.4% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth

2.4

Earnings Growth

3.8

Declining revenue: -0%

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

2.7

Value Rank

4.1

Quality Rank

6.9

GatesMomentum 1.5<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 1.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

48 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $51.03Resistance $62.47

Price Targets

$51

$63

A.Upside+14.9%

A.R:R1.5:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Momentum score 1.5/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:6d<=7d

Earnings

3/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is TECH stock a buy right now?

Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $54.71 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 6 days (event risk); Weak overall score: 4.7/10. Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $50.84. Score 4.7/10, moderate confidence.

What is the TECH stock price target?

Take-profit target: $62.88 (+15.0% upside). Prior stop was $50.84. Stop-loss: $50.84.

What are the risks of investing in TECH?

Earnings in 6 days (event risk); Weak overall score: 4.7/10; Weak growth.

Is TECH overvalued or undervalued?

Bio-Techne Corp trades at a P/E of 98.0 (forward 24.0). TrendMatrix value score: 5.1/10. Verdict: Sell.

What do analysts say about TECH?

23 analysts cover TECH with a consensus score of 4.0/5. Average price target: $72.

What does Bio-Techne Corp do?Bio-Techne develops and manufactures life science reagents, instruments, and services across Protein Sciences (~72% of...